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Abstract 
The synthesis of eleven novel antibacterial agents is reported. The structures are based on a C2-
symmetric binaphthyl scaffold which holds two identical chains consisting of a short linker, a basic 
amino acid and a small hydrophobic side chain. Antibacterial activity is revealed for a number of 
derivatives down to an MIC of 2 µg/mL (2 µM) against Staphylococcus aureus - comparable to 








The emergence of resistance to vancomycin in Gram-positive staphylococci and enterococci 
presents a serious health care challenge [1-5]. This challenge is heightened by cross-resistance to 
other antibacterials including linezolid [6]. In an attempt to overcome this resistance, high 
molecular weight cyclic peptides like oritavancin [7] or large vancomycin dimers linked via a rigid 
actinocin group [8] have been developed. Another strategy is to reduce molecular size with a view 
to the design of simpler cationic amino acids that possess additional features related to vancomycin. 
Such analogues could act in a similar fashion to vancomycin while concurrently maintaining the 
capability to bind strongly with the altered peptido-glycan cell wall moiety in vancomycin-resistant 
strains [3]. The same structural entity in sensitive strains would also be susceptible and thus 















minimisation strategy has been effectively pursued by Svendsen and co-workers with respect to 
other cationic peptidomimetics based on dipeptides which contain two cationic charges and two 
sterically bulky hydrophobic units [9,10,11]. Subsequently cationic tripeptide analogues were also 
developed [12,13]. The compounds have good activity against both Gram-positive (including 
MRSA) and Gram-negative bacteria, but activity against vancomycin-resistant strains was not 
assessed [12,13]. 
 
In our research the design principles we adopted [14] for the scaffolded amino acids included: 1) the 
presence of a basic amino acid residue to engage in an ionic interaction with the terminal 
carboxylate group of D-Ala or D-Lac in the cell wall peptide-glycan unit; 2) amino acid moieties 
for H-bond interactions with either of these two terminal groups; and 3) a 1,1'-binaphthyl system (or 
heteroaryl [15,16] or phenyl [17] systems) to enable hydrophobic interactions with the D-Ala methyl 
group or with other hydrophobic regions; such a system also offered the potential, through the 
atropisomers, for further stereochemical refinements if required. The initial exploration of these 
design principles involved amino acids contained within a scaffolded cyclic structure on the 2,2'-
dimethoxy-1,1'-binaphthyl system with the macrocyclic ring connected via the 3,3'-positions of the 
binaphthyl core and a D-lysine as the basic amino acid residue. This produced a derivative with 
good antibacterial activity (Minimum Inhibitory Concentration; MIC) of 15 µg/mL (16 µM) against 
S. aureus [14]. Testing of the deprotected acyclic precursors of these macrocycles, e.g. 1, revealed 
significant activities (e.g. 1, MIC = 2-4 µg/mL, 2-5 µM, against S. aureus) [18]. Further 
development of this class of compounds revealed that moving the aryl substituents from the 
binaphthyl 3,3'-positions to the 2,2'-aryloxy positions maintained activity (e.g. 2 (MIC = 4 µg/mL, 5 
µM) and 3 (MIC = 2 µg/mL, 2 µM) while allowing for a significantly easier synthetic access 
[19,20]. Our structure activity relationship (SAR) studies have already revealed the importance of 
the basic side chains within the molecule [21], however, the relative position of these amino acids 
has yet to be confirmed. The presence of the allyloxy substituent in 2 and 3 is a remnant of its 
requirement for use in a metathesis reaction to produce cyclic structures [14], and hence it could be 
replaced by additional basic amino acid units. The necessity of the binaphthyl aromatic unit in our 
acyclic antibacterial agents has been previously established - if the binaphthyl scaffold is replaced 
with an indole [15], carbazole [16], or a simple benzene unit [17], no significant antibacterial 
activity was found. We recently reported the importance of the presence of two basic amino acid 
side chains for activity across a broad spectrum of bacterial strains [20,22], however these reported 
analogues positioned these amino acids sequentially pendant from one of the naphthyl units of the 















different derivatives which maintain the binaphthyl hydrophobic scaffold but have incorporated the 
required basic amino acid moieties in chains attached to both binaphthyl 2,2'-oxy positions. 
 
Figure 1: Cyclic and acyclic hydrophobic scaffolded antibacterial agents containing amino acid 
moieties with MIC values against S. aureus [23]. 
 
2. Results and Discussion 
2.1 Chemistry 
Our target compounds are of the type exemplified by compounds 21 - 24 (Scheme 1). We 
incorporated a linker between the naphthyl and amino acid units as previous studies have shown 
that the presence of three contiguous methylene units can be tolerated within the structure (e.g. 2, 
MIC 5 µM, S. aureus) - this further ensured there was no steric interference from the binaphthyl 
units for any potential bonding with the peptide side chain. Both Arg and Lys side chains were used 
together with either the R- or S-binaphthyl anchors and a butanoic acid-based linking group. The 
amino acid chain was initially terminated by a benzyl ester as in one of our previous examples (3, 
Figure 1). However, we also further investigated a variety of ester and amide units to cap the chain. 
 
The facile synthesis of the first target structures 21-24 is outlined in Scheme 1. The protected Lys 
and Arg derivatives were esterified with either a methyl or benzyl moiety (6 - 8) before deprotection 
of the α-amino group in these esters to give the amines (9 - 11). These amino esters were then added 
to the (R)- [24] or (S)-binaphthyl scaffold, which had been chain extended at the 2,2'-positions with 
an oxybutanoic acid moiety (14 and 16), to yield derivatives 17 - 20. Deprotection of 17-20 gave 





































13 R = ethyl
14 R = H
b
15 R = ethyl






















































































































































Scheme 1. Synthesis of compound 21-24. Reagents and conditions: a) for 6 and 7: BnOH or 
MeOH, SOCl2, 0-70 ºC, overnight, for 8: MeOH, EDCI, HOBt, CH3CN, RT, 3 h; b) piperidine, 
CH3CN, RT, 3 h; c) ethyl 4-bromobutyrate, K2CO3, acetone, reflux, 24 h; d) LiOH, H2O, THF, RT, 
4 h; e) EDCI, HOBt, CH3CN, RT, 3 h; f) TFA, CH2Cl2, RT, 3 h to overnight, then 1 M HCl-Et2O.   
 
The arginine derivative 19 was also used to vary the ester terminus in the corresponding benzyl 
amide 28 and 2-pyridylmethyl ester 29 (Scheme 2). Similarly, the lysine derivative 20 was used to 
generate the analogues 34, 35 and 36 where the terminal methyl ester was replaced with a benzyl, 2-
pyridylmethyl and 1-naphthyl ester respectively (Scheme 3). Finally, a guanylation reaction of the 
lysine benzyl ester 34 and the lysine 1-naphthyl ester 36 provided the corresponding homoarginyl 
derivatives, 39 and 40 respectively.  
 
In all the reactions to produce the derivatives, there was no evidence for racemisation of the 
binaphthyl unit occurring. This is consistent with our previous results [14]-[22] and experience with 

















Scheme 2. Synthesis of compound 28 and 29. Reagents and conditions: a) LiOH, H2O, THF, RT, 
90 min, 74%; b) BnNH2 or 2-pyridinecarbinol, EDCI, HOBt, CH3CN, RT, 3 h; 27% (26), 64% (27); 






































31 R1 = Bn, R2 = Boc
32 R1 = 2-methylpyridyl, R2 = Boc
33 R1 = 1-naphthyl, R2 = Boc
c
34 R1 = Bn, R2 = H.HCl
35 R1 = 2-pyridylmethyl, R2 = H.HCl





Scheme 3. Synthesis of compound 34-36. Reagents and conditions: a) LiOH, H2O, THF, RT, 90 
min, 92%; b) PPh3, DIAD, THF, benzyl alcohol (for 31), 2-pyridinecarbinol (for 32), 1-
naphthalenemethanol (for 33), 0 ºC to RT, overnight; c) TFA, CH2Cl2, RT, 3 h, then 1 M HCl-Et2O, 












































37 R1 = Bn, R2 = Boc
38 R1 = 1-naphthyl, R2 = Boc
39 R1 = Bn, R2 = H.HCl




Scheme 4. Synthesis of compound 39 and 40. Reagents and conditions: a) Et3N, N,N'-bis(tert-
butoxycarbonyl)-N''-triflyl guanidine, CH2Cl2, RT, overnight, 79% (37), 61% (38); b) TFA, 
CH2Cl2, RT, overnight, then 1 M HCl-Et2O, 86% (39), 61% (40). 
 
2.2 Evaluation of Antibacterial Activities 
The results from the antibacterial testing of these compounds against S. aureus (ATCC6538P; 
vancomycin sensitive) and vancomycin sensitive and resistant strains of E. faecium (#243, 449, 820, 
987; clinical isolates) are summarised in Table 1. The most active compound againstS. ureus was 
the (S)-diarginine-based structure 21 with an MIC of 2 µg/mL, equipotent with vancomycin. In 
addition, this activity was not sensitive to the binaphthyl stereochemistry with similar activity being 
observed for the corresponding (R)-binaphthyl isomer 22. This result is not inconsistent with the 
binaphthyl scaffold having a general hydrophobic interaction role. The terminal ester appears to 
require a reasonable degree of hydrophobic steric bulk with the smaller methyl diester 23 howing 
notably less activity than 21 or 22. However, the introduction of a heteroatom into the terminal aryl 
ester, e.g. the corresponding 2-pyridylmethyl diester 29 with the potential for hydrogen-bonding 
interaction in this region, was detrimental with the compound showing very poor activity. This 
trend is emulated with the dilysine series with 34 (dibenzyl ester) showing the best activity, with 
both the larger dinaphthyl diester 36 and the 2-pyridylmethyl diester 35 showing poorer activity. By 
extending the length of the basic amino acid side chains, we produced the homoarginine derivatives 
39 and 40 with terminal benzyl and naphthyl esters respectively. The extra length in the side chains 
















With E. faecium, compounds 21 and 22 showed the best activity, a highlight being the moderate 
activity (MICs 31 µM) shown against the vancomycin resistant strains VRE449 and VRE820 in 
comparison to vancomycin which was completely ineffective (MIC >86 µM). Interestingly, a direct 
comparison between 21 and 28, where the only difference is the replacement of the terminal 
dibenzyl ester with a dibenzyl amide showed a similar trend for the vancomycin sensitive 
enterococcal strains, however the amide 28 was significantly less potent against the resistant strains 
compared to the corresponding ester derivative. A comparison between the activities shown for S. 
aureus and VRE987, which were both vancomycin sensitive strains, showed our derivatives to be 
essentially ineffective against the later. Indeed, generally the trends in activities against E. faecium 
were poor, with decreasing activity observed when the terminal ester was reduced in size (e.g. to a 
methyl ester), and when an aryl heteroatom was incorporated into the terminal ester. 
 
In general, the use of C2-symmetric systems of the type illustrated in Table 1 showed no particular 
advantage or insight into the antibacterial activities of our scaffolded amino acid molecules. 
Although the structures 21 and 22 showed equivalent activity to our previous acyclic lead 
compounds 2 and 3, this study was unable to improve antibacterial activities against E. faecium. We 
have since further developed our acyclic binaphthyl scaffolded amino acids and have shown that 
they possess consistently good activities, including against S. aureus and resistant strains of bacteria 
[20]. This current study has highlighted that the repositioning of the amino acid basic side chains 
relative to the scaffold and the terminal esters was particularly detrimental to the activity against the 
resistant strains tested and these results have assisted with the SAR picture developing for this class 
of inhibitors. 
 
Table 1: Antibacterial activities of our synthesised compounds  
 
S. aureus (ATCC 6538P), E. faecium #243, E. faecium #449, E. faecium #820, E. faecium #987. 

















In conclusion, some of the C2-symmetric scaffolded cationic amino acid derivatives synthesised 
here showed good activity against S. aureus, and in selected cases equalled the activity shown by 
our lead compounds and vancomycin. However, further development of this series was curtailed in 
the light of better activities shown by simpler compounds with just one side chain attached to the 
binaphthyl scaffold.  
 
4. Experimental Protocols 
4.1 General Notes 
Melting point determinations were carried out on a Gallenkamp melting point apparatus and are 
uncorrected. Chemical ionization (CI) and electron impact (EI) mass spectra were obtained on a 
Shimadzu QP-5000 mass spectrometer by a direct insertion technique with an electron beam energy 
of 70 eV. Electrospray ionization (ESI) mass spectra were obtained on a VG Autospec 
spectrometer. High-resolution mass spectra (HRMS) were determined on a micromass QTof2 
spectrometer using polyethylene glycol or polypropylene glycol as the internal standard. The m/z 
values are stated with their peak intensity as a percentage in parentheses. Proton and carbon nuclear 
magnetic resonance (NMR) spectra were obtained as specified on a Varian Mercury 300 MHz or 
Varian Inova 500 MHz spectrometer. Spectra were recorded in the specified deuterated solvent, and 
referenced to the residual non-deuterated solvent signal. Chemical shifts (δ) in ppm were measured 
relative to the internal standard. Multiplet (m) signals are reported from the centre of the peak; ‘app’ 
refers to apparent when describing some multiplets. Analytical thin layer chromatography (TLC) 
was carried out on Merck silica gel 60 F254 pre-coated aluminium plates with a thickness of 0.2 mm. 
All column chromatography was performed under ‘flash’ conditions on Merck silica gel 60 (230-
400 mesh). Chromatography solvent mixtures were measured by volume. All compounds were 
judged to be of greater than 95% purity based upon 1H NMR and TLC analysis. Starting materials 
and reagents were purchased from Sigma-Aldrich Pty Ltd or Auspep Pty Ltd and were used as 
received. Solvent extracts were dried over magnesium sulfate. 
All final tested compounds are fully characterized with the exception where LRMS revealed only an 
m/2 peak due to instrumentation limitations, the HRMS measurements on m/2 ions was not 
possible. 
 
4.2 General Protocols 















To a stirred solution of an acid (1 equiv.) and an amine (1 equiv.) in dry acetonitrile or DMF (5-10 
mL) was added EDCI (1.2 equiv.) and HOBt (1.2 equiv.). If the amine was a HCl salt then 1 
equivalent of DIPEA was also added. The reaction mixture was stirred overnight before the solvent 
was removed under reduced pressure and the resultant residue subjected to flash silica gel column 
chromatography (normally using 2% MeOH/CH2Cl2 as the eluant) to afford the desired compound. 
 
4.2.2 Protocol 2: N-Fmoc Deprotection 
To a stirred solution of the Fmoc-protected peptide in dry acetonitrile (5-10 mL) was added 
piperidine (0.1 mL). The resultant solution was then stirred at room temperature for 3 h. The solvent 
was then removed under reduced pressure and the resultant residue subjected to flash silica gel 
chromatography using a short column with 2% MeOH/CH2 l2 then 5% MeOH/CH2Cl2) upon 
removal of Fmoc by-products to afford the desired compound. 
 
4.2.3 Protocol 3: N-Boc and Pmc/Pbf Deprotection 
To a stirred solution of the protected peptide in CH2 l2 (2 mL) was added TFA (2 mL). The 
reaction mixture was stirred at room temperature for 3 h. before the solvent was removed under 
reduced pressure. After triturating twice more with CH2 l2 (2 mL), the residue was taken up in 
CH2Cl2 (2 mL) and treated with a 1M HCl/ether solution (2 mL), stirred for 1 min and then 
evaporated to dryness. This treatment with HCl was repeated twice more. For Boc-deprotection this 
is the final step, for Pmc/Pbf-deprotection the following is completed. The residue was taken up in 
the minimum required CH2Cl2 (or dry MeOH if insoluble in CH2Cl2), precipitated by the addition 
of diethyl ether and the solid collected by centrifugation. This step is repeated once more to remove 
the protecting group by-product. The resultant solid was then dried to yield the desired compound 
as its hydrochloride salt. 
 
4.2.4 Protocol 4: Esterification 
To an ice cold solution of an acid (1 equiv.) in dry THF (30 mL) was added DIAD (2.1 equiv.) and 
PPh3 (2.1 equiv.) under a nitrogen atmosphere. The alcohol (2.1 equiv.) was then added and the 
solution was allowed to warm to room temperature and was then stirred overnight. The solvent was 
then evaporated under reduced pressureand the crude product was purified by flash column 
chromatography with 0-5% MeOH/CH2Cl2 to yield an ester product. 
 






























To Fmoc-(R)-Arg(Pmc)-OH (1.00 g, 1.51 mmol) dissolved in dry MeOH (5 mL) was added thionyl 
chloride (0.2 mL). The solution was then heated at reflux overnight before being evaporated to 
dryness. Water (20 mL) was then added and the solution was extracted with CH2Cl2 (3 x 30 mL). 
The combined organic extracts were dried and evaporated to dryness to yield the desired product 
(952 mg, 93%) as a foamy white solid which was of sufficient purity to carry onto the next step. 1H 
NMR (300 MHz, CDCl3) δ 1.27 (s, 6H), 1.51-1.63 (m, 2H), 1.72-1.76 (m, 2H), 1.80 (t, J = 6.9 Hz, 
2H), 2.10 (s, 3H), 2.54-2.64 (m, 2H), 2.56 (s, 3H), 2.60 (s, 3H), 3.63 (s, 3H, OCH3), 4.12-4.16 (m, 
1H), 4.27-4.35 (m, 3H), 5.95 (d, J = 8.4 Hz, 1H, NH), 6.30 (br s, 1H, NH), 6.35 (br s, 2H, NH), 
7.26 (t, J = 7.4 Hz, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 7.5 Hz, 2H); 
13C NMR (75 MHz, CDCl3) δ 12.0, 17.4, 18.5, 21.3, 24.9, 26.6, 29.3, 32.6, 36.4, 40.5, 46.9, 52.2, 
66.9, 73.4, 117.7, 119.6, 123.7, 124.9, 126.8, 127.4, 133.1, 134.5, 135.1, 140.9, 143.4, 143.5, 153.2, 















The title compound was prepared via protocol 2, using Fmoc-(R)-Arg(Pmc)-OMe (7) (356 mg, 0.53 
mmol) to yield the desired product (186 mg, 80%) as a white foam [25]. 1H NMR (300 MHz, 
CDCl3) δ 1.30 (s, 6H), 1.46-1.62 (m, 3H), 1.66-1.76 (m, 1H), 1.74 (br s, 2H, NH2), 1.80 (t, J = 6.8 















3.45 (m, 1H), 3.67 (s, 3H, OCH3), 6.41 (s, 1H, NH); 
13C NMR (75 MHz, CDCl3) δ 12.0, 17.4, 18.4, 
21.3, 25.5, 26.7, 32.7, 40.6, 61.9, 53.8, 73.5, 117.8, 123.9, 133.3, 134.7, 135.3, 153.4, 156.2, 176.1.  
 










To a suspension of (S)-1,1'-binaphthalene-2,2'-diol (5.0 g, 17.5 mmol) and anhydrous potassium 
carbonate (12.0 g, 87.6 mmol) dissolved in acetone (200 mL), was added ethyl bromobutyrate (6.0 
mL, 2.2 equiv.) under a nitrogen atmosphere. The mixture was then heated at reflux for 24 h. before 
being evaporated to dryness and the residue partitioned between ethyl acetate (100 mL) and water 
(100 mL). The organic layer was then washed with water (2 x 50 mL) before being dried and 
evaporated to yield an oil (7.56 g, 85%) which was used in the next step without further 
purification. 1H NMR (300 MHz, CDCl3) δ 1.17 (t, J = 7.2 Hz, 6H), 1.73-1.79 (m, 4H), 1.87-1.94 
(m, 4H), 3.97-4.08 (m, 8H), 7.18-7.26 (m, 4H), 7.31-7.36 (m, 2H), 7.39 (d, J = 8.8 Hz, 2H), 7.84 (d, 
J = 8.0 Hz, 2H), 7.92 (d, J = 8.8 Hz); 13C NMR (75 MHz, CDCl3) δ 14.0, 24.5, 29.9, 59.9, 68.3, 
115.5, 120.4, 123.5, 125.2, 126.1, 127.7, 129.15, 129.20, 133.9, 153.9, 173.1. MS (EI, +ve) m/z 514 
(100%) [M]. HRMS (ESI, +ve) calcd for C32H35O6 515.244, found 515.2434. 
 










To 15 (598 mg, 1.52 mmol) dissolved in THF (30 mL) was added a solution of LiOH (250 mg, 
10.50 mmol) in water (20 mL). After stirring at RT for 4 h, diethyl ether was added and the layers 
were separated. The aqueous layer was then acidified with diluted HCl solution. This was then 
extracted with diethyl ether (3 x 20 mL). The combined extracts were dried and the solvent was 
evaporated under reduced pressure to yield 16 (342 mg, 64%) as a white foam. 1H NMR (300 MHz, 
CDCl3) δ 1.52-2.00 (m, 8H), 3.81-4.05 (m, 4H), 7.14-7.20 (m, 4H), 7.25-7.30 (m, 2H), 7.35 (d, J = 















(75 MHz, CDCl3) δ 24.1, 29.6, 68.1, 115.6, 120.4, 123.7, 125.2, 126.3, 127.9, 129.30, 129.32, 




























The title compound was prepared via protocol 1, using 9 [21] (159 mg, 0.30 mmol; prepared via 4 
and 6) and 16 (68.7 mg, 0.15 mmol) to yield 17 as a white solid (124 mg, 59%). 1H NMR (300 
MHz, CDCl3) δ 1.25 (s, 12H), 1.32-1.39 (m, 4H), 1.54-1.81 (m, 16H), 2.06 (s, 6H), 2.42-2.60 (m, 
4H), 2.50 (s, 6H), 2.53 (s, 6H), 2.94-3.15 (m, 4H), 3.74-3.78 (m, 2H), 3.94-3.97 (m, 2H), 4.29-4.40 
(m, 2H), 5.04 (s, 4H) 6.12 (br s, 2H, NH), 6.23 (br s, 4H, NH), 6.43 (d, J = 7.2 Hz, 2H, NH), 7.08 
(d, J = 8.4 Hz, 2H), 7.16 (dist t, 2H), 7.18-7.28 (m, 12H), 7.32 (d, J = 9.0 Hz, 2H), 7.80 (d, J = 8.4 
Hz, 2H), 7.86 (d, J = 9.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 12.0, 17.4, 18.5, 21.3, 25.1, 25.3, 
26.7, 29.1, 31.7, 32.6, 40.5, 51.9, 67.0, 68.2, 73.6, 115.7, 117.9, 120.3, 123.7, 124.0, 125.2, 126.3, 
127.9, 128.1, 128.3, 128.5, 129.2, 129.4, 133.2, 134.0, 134.7, 135.2, 135.3, 153.5, 153.8, 










































The title compound was prepared via protocol 1, using 9 [21] (125 mg, 0.236 mmol) and 14 [24] 
(45 mg, 0.098 mmol) to yield 18 as a white solid (123 mg, 86%). 1H NMR (300 MHz, CDCl3) δ 
1.25 (s, 12H), 1.28-1.35 (m, 4H), 1.43-1.75 (m, 16H), 2.07 (s, 6H), 2.52 (s, 6H), 2.53-2.57 (m, 4H), 
2.54 (s, 6H), 2.95-3.14 (m, 4H), 3.77-3.82 (m, 2H), 3.94-3.99 (m, 2H), 4.34-4.41 (m, 2H), 5.04 (s, 
4H), 6.05 br s, 2H, NH), 6.19 (br s, 2H, NH), 6. 21 (s, 4H, NH), 7.10, d, J = 8.5 Hz, 2H), 7.15-7.20 
(m, 2H), 7.22-7.31 (m, 12H), 7.33 (d, J = 9.1Hz, 2H), 7.80 (d, J = 7.9 Hz, 2H), 7.87 (d, J = 9.1 Hz, 
2H). 13C NMR (75 MHz, CDCl3) δ 12.0, 17.4, 18.5, 21.3, 24.9, 25.2, 26.7, 29.2, 31.5, 32.6, 40.5, 
51.7, 67.0, 73.5, 76.6, 115.4, 117.9, 120.2, 123.7, 124.0, 125.3, 126.3, 127.9, 128.1, 128.4, 128.5, 
129.1, 129.4, 133.3, 134.0, 134.7, 135.2, 135.3, 153.5, 153.7, 156.1,171.7, 173.1. MS (ESI +ve) m/z




























The title compound was prepared via protocol 1, using (R)-Arg(Pmc)-OMe (10) (40 mg, 0.088 
mmol) and 16 (20 mg, 0.044 mmol) to yield 19 as a white solid (18 mg, 31%). 1H NMR (300 MHz, 
CDCl3) δ 1.28 (s, 12H), 1.35-1.40 (m, 4H), 1.48-1.55 (m, 2H), 1.60-1.78 (m, 14H), 2.09 (s, 6H), 















4.00-4.05 (m, 2H), 4.32-4.39 (m, 2H), 6.06 (br s, 2H, NH), 6.18-6.29 (m, 6H, NH), 7.13 (d, J = 8.7 
Hz, 2H), 7.21 (app t, 2H), 7.32 (app t, 2H), 7.39 (d, J = 9.0 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.92 























The title compound was prepared via protocol 1, using 16 (50 mg, 0.11 mmol) and (R)-Lys(BOC)-
OMe (11) (68 mg, 0.23 mmol) to yield the desired product 20 as an off white solid (90 mg, 87%). 
Rf = 0.44 (5% MeOH/CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 1.15-1.26 (m, 4H), 1.30-1.55 (m, 
6H), 1.43 (s, 18H), 1.59-1.76 (m, 10H), 2.97-3.02 (m, 4H), 3.73 (s, 6H), 3.84-3.91 (m, 2H), 4.11-
4.18 (m, 2H), 4.42-4.49 (m, 2H), 4.53 (br s, 2H, 2 x NHBoc), 5.62 (d, J = 8.2 Hz, NH), 7.16-7.19 
(m, 2H), 7.23-7.58 (m, 2H), 7.33-7.38 (m, 2H), 7.45 (d, J = 9.1 Hz, 2H), 7.91 (d, J = 8.2 Hz, 2H), 
7.99 (d, J = 8.8 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 22.4, 24.9, 28.4, 29.4, 31.7, 32.0, 33.9, 
40.1, 51.6, 52.2, 68.1, 79.0, 115.6, 120.4, 123.6, 125.2, 126.2, 127.8, 127.9, 129.2, 129.3, 134.0, 






































The title compound was prepared via protocol 3, using 17 (124 mg, 0.089 mmol) to yield 21 as a 
white solid (65.9 mg, 73%). 1H NMR (300 MHz, CD3OD) δ 1.42-2.00 (m, 16H), 3.00-3.17 (m, 4H), 
3.90-3.97 (m, 4H), 4.23-4.35 (m, 2H), 5.02-5.12 (m, 4H), 6.96-6.99 (m, 2H), 7.04-7.15 (m, 2H), 
7.16-7.34 (m, 12H), 7.37-7.49 (m, 2H), 7.80 (d, J = 7.8 Hz, 2H), 7.89 (d, J = 8.7 Hz, 2H); 13C NMR 
(75 MHz, CD3OD) δ 26.3, 26.7, 29.4, 31.7, 32.8, 41.8, 53.4, 67.9, 69.6, 116.7, 121.4, 124.6, 126.2, 
127.2, 129.1, 129.3, 129.4, 129.6, 130.5, 130.8, 135.3, 137.0, 155.4, 158.4,173.0, 173.2. MS (ESI 
+ve) m/z 951 (5%) [M+H]+; 476 (100) [M+H]2+. HRMS (ESI, +ve) calcd for C54H63N8O8 951.4769, 
found 951.4805.  
 
Dibenzyl (2R)-7,7'-((R)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-di(3-guanidinopropyl)-3,3'-diaza-4,4'-




















The title compound was prepared via protocol 3, using 18 (120 mg, 0.081 mmol) to yield 22 as a 
white solid (71 mg, 86%). 1H NMR (300 MHz, CD3OD) δ 1.54-1.61 (m, 4H), 1.63-1.70 (m, 6H), 
1.78-1.87 (m, 2H), 1.90-1.95 (m, 4H), 3.10-3.15 (m, 4H), 3.90-4.04 (m, 4H), 4.31-4.36 (m, 2H), 
5.10 (ABq, J = 12.3 Hz, 4H), 7.00-7.03 (m, 2H), 7.10-7.15 (m, 2H), 7.23-7.32 (m, 12H), 7.45 (d, J 
= 9.0 Hz, 2H), 7.83 (d, J = 7.9 Hz, 2H), 7.93 (d, J = 9.1 Hz, 2H); 13C NMR (75 MHz, CD3OD) δ 







































The title compound was prepared via protocol 3, using 19 (20 mg, 0.015 mmol) to yield 23 as a 
white solid (9 mg, 64%). 1H NMR (300 MHz, CD3OD) δ 1.54-1.63 (m, 10H), 1.73-1.95 (m, 6H), 
3.07-3.23 (m, 4H), 3.69 (s, 6H), 3.78-3.91 (m, 2H), 3.92-4.06 (m, 2H), 4.25-4.29 (m, 2H), 6.69-6.82 
(m, 2H), 6.93-7.00 (m, 4H), 7.38 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 7.7 Hz, 2H), 7.81 (d, J = 8.3 Hz, 
2H). 13C NMR (75 MHz, CD3OD) δ 26.3, 26.7, 29.8, 32.9, 41.9, 52.9, 55.1, 69.7, 116.8, 121.7, 
124.7, 126.3, 127.3, 129.1, 130.5, 130.9, 135.4, 155.6, 158.6, 174.9, 175.7. MS (ESI +ve) m/z: 401 
(100%) [M+2H]2+. HRMS (ESI +ve) calcd for C42H55N8O8 799.4143, found 799.4133. 
 
Dimethyl (2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-dibutylamino-3,3'-diaza-4,4'-


















The title compound was prepared via protocol 3, using 20 (88 mg, 0.093 mmol) to yield the desired 
product 24 as an off white solid (50 mg, 76%). 1H NMR (300 MHz, CD3OD) δ 1.22-1.52 (m, 4H), 















4.40 (m, 2H), 7.04 (dist d, J = 8.0 Hz, 2H), 7.16-7.21 (m, 2H), 7.23-7.39 (m, 2H), 7.48-7.61 (m, 
2H), 7.88-7.90 (m, 2H), 7.94-8.08 (m, 2H); 13C NMR (75 MHz, CD3OD) δ 23.8, 26.7, 27.9, 31.8, 
32.8, 40.5, 52.8, 53.3, 69.7, 116.8, 124.5, 124.7, 126.2, 127.2, 129.1, 130.5, 130.8, 135.4, 155.5, 
173.8, 175.6. MS (ESI +ve) m/z 743.3 (10%) [M+H] +; 372.6 (100) [M+2H]2+. HRMS (ESI +ve) 
calcd for C42H55N4O8 743.4020, found 743.4033. 
 
(2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-di{3-[(2,3-dihydro-2,2,4,6,7-pentamethyl-2H-1-

























To a soln of 19 (200 mg) in THF (20 mL), was added a solution of LiOH (75 mg, 3.1 mmol) in 
water (10 mL). After stirring at room temperature for 90 min, ethyl acetate was added and the layers 
were separated. The aqueous layer was then acidified with a diluted potassium bisulphate solution. 
This was then extracted with CH2Cl2 (3 x 20 mL) and then the solvent was removed under reduced 
pressure to yield 25 (145 mg, 74%) as a white foam. 1H NMR (300 MHz, CD3OD) δ 1.23 (s, 12H), 
1.35-1.97 (m, 20H), 2.03 (s, 6H), 2.30-2.63 (m, 10H), 2.94-3.22 (m, 4H), 3.66-3.86 (m, 2H), 3.89-
4.09 (m, 2H), 4.20-4.42 (m, 2H), 6.15-6.62 (m, 6H), 7.01-7.11 (m, 4H), 7.22-7.32 (m, 4H), 7.68-
7.81 (m, 4H), 8.51 (br s, 2H); 13C NMR (75 MHz, CDCl3) δ 12.1, 17.4, 18.5, 21.3, 25.2, 26.7, 28.7, 
31.6, 40.5, 52.5, 67.9, 68.1, 73.7, 112.0, 115.6, 118.1, 120.3, 123.6, 124.1, 125.2, 126.4, 127.9, 
128.4, 129.2, 133.9, 134.9, 135.4, 138.1, 153.8, 156.2, 174.3, 175.2. MS (ESI +ve) m/z 1326 (80%) 








































The title compound was prepared via protocol 1 using 25 (70 mg, 0.054 mmol) and benzylamine 
(0.1 mL, 0.92 mmol) to yield the coupled product 26 (21.4 mg, 27%). This was then deprotected 
directly via protocol 3 to yield 28 (10 mg, 75%). 1H NMR (300 MHz, CD3OD) δ 1.51-1.85 (m, 
12H), 1.95-2.02 (m, 4H), 3.09-3.22 (m, 4H, 2 x CH2N), 3.92-4.08 (m, 4H, 2 x CH2O), 4.30-4.35 (m, 
6H, 2 x (CH (Arg) and CH2Ph)), 7.03 (d, J = 8.4 Hz, 2H, ArH), 7.16-7.33 (m, 14H, ArH), 7.49 (d, J 
= 9.0 Hz, 2H, ArH), 7.88 (d, J = 8.1 Hz, 2H, ArH), 7.97 (d, J = 9.0 Hz, 2H, ArH), 8.47 (app t, 2H, 
NH); 13C NMR (75 MHz, CD3OD) δ 26.3, 30.3, 32.9, 41.9, 44.0, 54.3, 69.7, 116.8, 121.6, 124.7, 
126.3, 127.2, 128.2, 128.4, 129.1, 129.6, 130.5, 130.9, 135.4, 139.7, 135.5, 158.5, 174.0, 175.7. MS 
(ESI +ve) m/z 949 ([M+H]+, 10%), 475 ([M+2H]2+, 100). HRMS (ESI +ve) calcd for C54H65N10O6 
949.5089, found 949.5071. 
 
Di(1-methylpyridyl) (2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-di(3-guanidinopropyl)-3,3'-






















The protected precursor was prepared via protocol 1 using 25 (60 mg, 0.046 mmol) and 2-
pyridinemethanol (0.02 ml) to yield 27 as an impure light brown solid (44 mg, 64%, MS (ESI +ve) 
m/z 1485.5 (10%) [M+H]+; 743.3 (20) [M+2H]2+). This was then deprotected directly via protocol 3 
to yield 29 as an off white solid (28 mg, 90%). 1H NMR (300 MHz, CD3OD) δ 1.47-1.84 (m, 10H), 















Hz, 4H), 6.94-6.96 (m, 2H), 7.09-7.14 (m, 2H), 7.21-7.26 (m, 2H), 7.43-7.46 (m, 2H), 7.80-7.98 
(m, 8H), 8.41-8.46 (m, 2H), 8.68-8.80 (m, 2H); 13C NMR (75 MHz, CD3OD) δ 26.3, 26.7, 29.0, 
32.7, 41.9, 53.5, 63.6, 69.9, 116.7, 121.4, 124.7, 126.2, 127.2, 127.2, 127.5, 129.0, 130.5, 130.8, 
135.3, 143.7, 147.5, 152.2, 155.5, 158.5, 172.5, 176.0. MS (ESI +ve) m/z 477.5 (100%) [M+2H]2+. 
 
(2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-di[(1,1'-dimethylethoxycarbonylamino)butyl]-3,3'-




















To a soln of 20 (200 mg, 0.212 mmol) in THF (20 mL), was added a solution of LiOH (75 mg, 3.14 
mmol) in water (10 mL). After stirring at room temperature for 90 min, ethyl acetate was added and 
the layers were separated. The aqueous layer was then acidified with a dilute potassium bisulfate 
solution. This was then extracted with CH2Cl2 (3 x 20 mL) and then the solvent was removed under 
reduced pressure to yield 30 (178 mg, 92%) as a white foam. 1H NMR (300 MHz, CDCl3) δ 1.21-
1.26 (m, 4H), 1.30-1.62 (m, 4H), 1.40 (s, 18H), 1.62-1.86 (m, 12H), 2.90-3.11 (m, 4H), 3.89-3.91 
(m, 2H), 4.01-4.15 (m, 2H), 4.38-4.54 (m, 2H), 4.79-4.81 (m, 2H, 2 x NHBoc), 6.20-6.40 (m, 2H, 2 
x NH), 7.12 (d, J = 8.1 Hz, 2H), 7.19 (app t, 2H), 7.30 (t, J = 7.2 Hz, 2H), 7.41 (d, J = 9.0 Hz, 2H), 
7.84 (d, J = 7.8 Hz, 2H), 7.92 (d, J = 8.7 Hz, 2H), 10.51 (br s, 2H, 2 x OH);13C NMR (75 MHz, 
CDCl3) δ 20.7, 22.4, 25.0, 29.2, 31.3, 31.5, 40.0, 51.7, 68.1, 79.2, 115.8, 120.5, 123.7, 125.2, 126.3, 
127.8, 129.2, 129.3, 134.0, 153.7, 156.2, 158.0, 173.5, 175.5. MS (ESI +ve) m/z 937 (80%) 
[M+Na]+; 915 (100) [M+H]+. 
 
Dibenzyl (2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-dibutylamino-3,3'-diaza-4,4'-
































The title compound was prepared via protocol 4, using 30 (120 mg, 0.131 mmol), triphenyl 
phosphine (73 mg, 0.278 mmol), DIAD (0.055 ml, 0.275 mmol) and BnOH (0.05 mL, 0.275 mmol). 
The Boc-protected intermediate 31 eluted at the same time as a reaction by product, and so this 
material was then deprotected via protocol 3 to yield the desired product 34 as a pale yellow 
hydrochloride salt (101 mg, 80%). 1H NMR (300 MHz, CD3OD) δ 1.20-1.40 (m, 4H), 1.49-1.72 
(m, 10H), 1.67-1.84 (m, 2H), 1.85-2.01 (m, 4H), 2.70-2.87 (m, 4H), 3.82-4.06 (m, 4H), 4.27-4.32 
(m, 2H), 5.08 (ABq, J = 12.3 Hz, 4H), 6.98 (dist d, J = 8.5 Hz, 2H), 7.11 (app t, 2H), 7.21-7.36 (m, 
10H), 7.41-7.50 (m, 2H), 7.55-7.61 (m, 2H), 7.81 (d, J = 7.9 Hz, 2H), 7.91 (d, J = 8.8 Hz, 2H); 13C 
NMR (75 MHz, CD3OD) δ 21.2, 22.6, 25.6, 26.8, 30.6, 31.7, 39.3, 52.4, 66.8, 68.5, 115.6, 120.4, 
123.6, 125.1, 126.1, 128.0, 128.2, 128.3, 218.5, 128.8, 129.0, 129.4, 129.7, 131.8, 132.0, 132.7, 
134.2, 136.1, 154.3, 172.0, 174.6. MS (ESI +ve) m/z 895.5 (10%) [M+H]+; 825.4 (40) [M-lys]+; 






















The crude Pmc protected precursor 32 was prepared via protocol 4, using 30 (120 mg, 0.131 mmol) 
and 2-pyridinemethanol (0.026 mL) to yield an impure light brown solid. This was then deprotected 
via protocol 3 to yield 35 as an off white solid (68 mg, 54%). 1H NMR (300 MHz, CD3OD) δ 1.28-
1.51 (m, 4H), 1.52-1.79 (m, 8H), 1.80-2.03 (m, 4H), 2.78-2.94 (m, 4H), 3.94-3.98 (m, 4H), 4.25-















7.44 - 7.47 (m, 2H), 7.82 (d, J = 7.9 Hz, 2H), 7.86-7.96 (m, 4H), 7.99 - 8.01 (m, 2H), 8.41-8.52 (m 
2H), 8.74-8.75 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 26.3, 26.7, 29.4, 31.7, 32.8, 41.8, 53.4, 67.9, 
69.6, 116.7, 121.4, 124.6, 126.2, 127.2, 129.1, 129.3, 129.4, 129.6, 130.5, 130.8, 135.3, 137.0, 





















The title compound was prepared via protocol 4, using 30 (60 mg, 0.066 mmol), triphenylphosphine 
(73 mg, 278 mmol), DIAD (0.055 ml, 0.275 mmol) and 1-naphthalene methanol (45 mg, 0.028 
mmol). The Boc-protected intermediate 33 eluted at the same time as a reaction by product, and so 
this material was then deprotected via protocol 3 to yield the desired product 36 as a pale yellow 
hydrochloride salt (58 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 1.19-1.25 (m, 4H), 1.48-1.72 (m, 
12H), 1.78-1.94 (m, 4H), 2.64-2.68 (m, 4H), 3.80-3.93 (m, 4H), 4.22-4.45 (m, 2H), 5.54 (ABq, J = 
12.3 Hz, 4H), 6.96-7.00 (m, 2H), 7.11 (app t, 2H), 7.23 (app t, 2H), 7.32-7.50 (m, 10H), 7.73-7.90 
(m, 8H), 7.95 (d J = 8.4 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 23.6, 26.5, 27.8, 31.6, 32.7, 40.3, 
53.6, 66.3, 69.5, 116.7, 121.4, 124.6, 126.2, 126.3, 127.1, 127.2, 127.7,128.9, 129.0, 129.7, 130..5, 
130.7, 132.4, 132.8, 132.9, 135.1, 135.3, 142.9, 155.3, 173.1, 175.6. MS (ESI +ve) m/z 995.5 (10%) 
[M+H] +; 825.4 (40) [M-lys]+; 448.7 (100) [M+2H]2+. HRMS (ESI +ve) calcd for C62H67N4O8 













































To a soln of 34 (20 mg, 0.021 mmol) in CH2Cl2 (2 mL) was added triethylamine (0.09 mL) and 
N,N'-bis(tert-butoxycarbonyl)-N''-triflylguanidine (25 mg, 0.062 mmol) under nitrogen. The 
solution was allowed to stir overnight before being evaporated to dryness. The resultant residue was 
then subjected to flash column chromatography using 2% MeOH/CH2Cl2 as the eluant to yield the 
desired compound 37 as a pale yellow oil (23 mg, 79%). 1H NMR (300 MHz, CDCl3) δ 1.11-1.23 
(m, 4H), 1.38-1.61 (m, 10H), 1.48 (s, 18H), 1.49 (s, 18H), 1.65-1.80 (m, 6H), 3.20-3.32 (m, 4H), 
3.79-3.86 (m, 2H), 4.06-4.11 (m, 2H), 4.41-4.48 (m, 2H), 5.16 (ABq, J = 12.3 Hz, 4H), 5.54 (d, J = 
8.2 Hz, 2H, 2 x NH), 7.16 (dist d, J = 8.2 Hz, 2H), 7.23-7.27 (m, 2H), 7.31-7.40 (m, 15H), 7.44-
7.52 (m, 1H), 7.53-7.78 (m, 2H), 7.87 (d, J = 7.9 Hz, 2H), 7.94 (d, J = 9.1 Hz, 2H), 8.28 (br s, NH); 
13C NMR (75 MHz, CDCl3) δ 22.5, 24.8, 28.0, 28.2, 28.4, 31.6, 31.8, 40.5, 51.7, 67.1, 68.0, 79.4, 
83.2, 107.8, 115.6, 120.4, 121.5, 123.8, 125.4, 126.4, 128.0, 128.3, 128.5, 128.6, 129.2, 129.4, 
132.0, 132.1, 134.1, 135.2, 153.2, 153.8, 156.1, 163.4, 172.0, 172.7. MS (ESI +ve) m/z 1401.7 













































To a soln of 36 (47 mg, 0.044 mmol) in CH2Cl2 (2 mL) was added triethylamine (0.19 ml) and 
N,N'-bis(tert-butoxycarbonyl)-N''-triflylguanidine (53 mg, 0.13 mmol) under nitrogen. The solution 
was allowed to stir overnight before being evaporated to dryness. The resultant residue was then 
subjected to flash column chromatography eluting with 2% MeOH/CH2Cl2 to yield the desired 
compound 38 as an off white solid (40 mg, 61%). 1H NMR (300 MHz, CDCl3) δ 0.99-1.57 (m, 
14H), 1.47 (s, 18H), 1.48 (s, 18H), 1.63-1.71 (m, 6H), 3.11-3.18 (m, 4H), 3.70-3.77 (m, 2H), 3.97-
4.03 (m, 2H), 4.38-4.45 (m, 2H), 5.51 (d, J = 7.9 Hz, 2H, NH), 5.61 (ABq, J = 12.3 Hz, 4H), 7.12 
(dist d, J = 7.9 Hz, 2H), 7.18-7.32 (m, 6H), 7.44-7.60 (m, 8H), 7.78-7.82 (m, 4H), 7.87-7.92 (m, 
4H), 7.97 (dist d, J = 7.9 Hz, 2H), 8.24 (br s, 2H, NH); 13C NMR (75 MHz, CDCl3) δ 22.4, 24.8, 
28.0, 28.2, 28.3, 31.6, 40.5, 51.8, 53.4, 65.6, 67.9, 79.5, 83.2, 115.5, 120.4, 121.5, 123.4, 123.8, 
125.2, 126.1, 126.4, 126.7, 128.0, 128.8, 129.2, 129.4, 129.7, 130.7, 131.5, 133.7, 134.0, 153.2, 
153.6, 156.1, 163.3, 172.0, 172.9. MS (ESI +ve) m/z 1501.8 (10%) [M+Na]+; 1479.7 (10) [M+H]+; 
740.5 (20) [M+2H]2+. 
 
Dibenzyl (2R)-7,7'-((S)-1,1'-binaphthyl-2,2'-bisoxy)-2,2'-di(3-guanidinobutyl)-3,3'-diaza-4,4'-






















The title compound was prepared via protocol 3, using 37 (20 mg, 0.014 mmol) to yield the desired 
product 39 as a light brown solid (15 mg, 86%). 1H NMR (300 MHz, CDCl3) δ 1.16-1.31 (m, 4H), 
1.41-1.32 (m, 12H), 1.36-1.49 (m, 4H), 3.06-3.09 (m, 4H), 3.96-4.04 (m, 4H), 4.24-4.36 (m, 2H), 
5.06-5.16 (m, 4H), 7.01 (dist d, J = 8.1 Hz, 2H), 7.17-7.20 (m, 2H), 7.30-7.31 (m, 9H), 7.44-7.55 
(m, 3H), 7.58-7.65 (m, 2H), 7.85 (t, J = 6.9 Hz, 2H), 7.93-7.99 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 23.9, 26.7, 29.3, 32.0, 32.1, 32.8, 42.2, 67.9, 69.7 (CH2), 53.4 (CH), 116.8, 124.7, 126.3, 
127.3, 129.1, 129.3, 129.4, 129.6, 130.5 (ArCH), 121.6, 130.9, 135.4, 137.2, 155.5 (ArC), 158.6 
(CN3), 173.3, 175.7 (CO). MS (ESI +ve) m/z 490.5 (60%) [M+2H]
2+; 452.4 (100) [M+H-Ph]2+; 







































The title compound was prepared via protocol 3, using 38 (38 mg, 0.026 mmol) to yield the desired 
product 40 as a light brown solid (18 mg, 61%). 1H NMR (300 MHz, CDCl3) δ 1.09-1.45 (m, 6H), 
1.46-1.80 (m, 10H), 1.81-1.98 (m, 4H), 2.85-3.00 (m, 2H), 3.02-3.15 (m, 2H), 3.83-4.04 (m, 4H), 
4.20-4.35 (m, 2H), 5.49-5.37 (m, 4H), 6.98-7.02 (m, 2H), 7.13-7.18 (m, 2H), 7.22-7.30 (m, 2H), 
7.33-7.51 (m, 10H), 7.79-7.98 (m, 10H); 13C NMR (75 MHz, CDCl3) δ 22.7, 22.8, 25.5, 25.55, 
28.0, 28.1, 30.7, 30.8, 31.55, 31.6, 40.95, 41.0, 52.2, 52.5, 65.2, 68.3, 68.5, 115,5, 115.6, 120.35, 
120.4, 123.5, 125.1, 125.2, 125.5, 126.0, 126.1, 126.5, 127.8, 127.9, 128.6, 129.3, 129.4, 129.65, 
129.7, 131.4, 131.8, 134.1, 134.2, 154.25, 154.3, 157.4, 172.1, 172.8, 174.5. MS (ESI +ve) m/z 
540.4 (20%) [M+2H]2+; 477.3 (95) [M+H-naphthyl]2+; 414.4 (100) [M+H-2 x naphthyl]2+. HRMS 
(ESI +ve) calcd for C64H71N8O8 1079.5395, found 1079.5409. 
 
4.4 Determination of Minimum Inhibitory Concentration (MIC) 
MIC studies were performed on Staphylococcus aureus wild type (ATCC 6538P) in Luria Broth. 
MIC determinations for wild type and clinical isolates of Enterococcus faecium were conducted by 
growth in Enterococcosal broth (Becton Dickinson Microbiology Systems). Briefly, overnight 
stationary phase cultures were diluted 1:1000 into fresh media and then incubated with two fold 
dilutions of compound in media, typically with a highest concentration of 125 µg/mL, in a 96 well 
plate. Plates were incubated overnight at 37 ºC and the MIC recorded as the highest concentration at 
which bacterial growth was observed. Dilution factors give rise to concentrations of 125, 62.5, 31.3, 
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